CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-15). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2626 · Search date 2026-08-15 · Methodology v0.7

Hydrophilic intermittent catheter,
does it really help with Reduced antibiotic-treated symptomatic urinary tract infection after acute spinal cord injury?

30-Second Summary
C
Evidence Grade C · 54 · Safety caution
A symptomatic-UTI reduction signal exists in early acute spinal cord injury, but independent confirmation is limited.
Intermittent catheterization can cause urethral trauma, bleeding, and infection, so correct sizing and aseptic or clean-technique training are important. Resistance, bleeding, fever, or new urinary symptoms warrant clinical review.
What the
research shows
The grade is C. In a 224-person multicenter trial, SpeediCath reduced the daily hazard of a first antibiotic-treated symptomatic UTI by 33% and inpatient-rehabilitation incidence by 21% versus an uncoated PVC catheter. The trial was open label, fewer participants contributed to the analyzable survival data than were randomized, an investigator overlapped with the earlier 56-person trial, and Coloplast supported the 2011 trial, giving C with 54 points.
What the
ads claim
A ready-lubricated hydrophilic surface is a real product property, but it does not establish infection prevention for every user and duration. The clinical signal is limited to early rehabilitation after acute traumatic spinal cord injury and the tested products.
*

Useful facts when choosing a product

  • The 2011 trial compared a new SpeediCath at each use with externally lubricated uncoated Conveen PVC.
  • Diana D. Cardenas participated in both the 2009 and 2011 reports.
  • Unlike verdict 2531 on dialysis central-line infection, this verdict concerns intermittent catheterization and UTI after spinal cord injury.
Gap Measurement · Verdict 2626 · C 54
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Cardenas and Hoffman enrolled 56 people in 2009, with 45 completing; at least one antibiotic-treatment episode occurred in 50% versus 70%. That trial was supported by NIDRR and US Department of Education grant H133N000003 and stated that no commercial party provided benefits to the authors. The 2011 trial randomized 224 people with traumatic spinal cord injury of less than three months at 15 North American centers to SpeediCath or uncoated Conveen PVC and followed them for up to six months. Time to first antibiotic-treated symptomatic UTI improved, with a 33% lower daily hazard and 21% lower inpatient incidence. Cardenas appeared in both reports, and the 2011 study was supported by Coloplast A/S. No registration number was confirmed.

02

Why this is classified as C (54)

A significant benefit in clinical infection was offset by investigator overlap, manufacturer support, open treatment, and incomplete analysis, giving C with 54 points.

Counterpoint. C does not mean no effect. It means a positive acute-spinal-cord-injury signal lacks sufficiently independent, methodologically complete confirmation.

Rejudgment record. Cross-check applied — The two original reports were checked for author overlap, analyzed populations, infection definitions, outcomes, and Coloplast support

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI1Mixed funding sources
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Delayed first antibiotic-treated symptomatic UTICThe 224-person trial reported a 33% lower daily hazard.
Reduced symptomatic UTI during inpatient rehabilitationCInpatient incidence was 21% lower.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Cardenas DD, Hoffman JM. 2009Randomized controlled trial23Supported by NIDRR and US Department of Education grant H133N000003; the paper states that no commercial party provided benefits to the authorsAntibiotic-treated symptomatic UTIAt least one antibiotic-treatment episode occurred in 50% versus 70%, P=.18; total treated episodes were lower, but symptomatic UTI incidence itself was not significantly different.Small earlier trial centered on completers
Cardenas DD, Moore KN, Dannels-McClure A, et al. 2011Prospective open randomized parallel trial at 15 North American centers6The study was supported by Coloplast A/STime to first antibiotic-treated symptomatic UTI and total symptomatic UTIsDaily hazard of first UTI was 33% lower; inpatient incidence was 21% lower, P<.05.Pivotal direct trial with analytic-population and masking limitations
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-15).

Cardenas DD, Hoffman JM. Hydrophilic catheters versus noncoated catheters for reducing the incidence of urinary tract infections: a randomized controlled trial. Arch Phys Med Rehabil. 2009;90(10):1668-1671. PMID: 19801054. DOI: 10.1016/j.apmr.2009.04.010.
checked
Cardenas DD, Moore KN, Dannels-McClure A, et al. Intermittent catheterization with a hydrophilic-coated catheter delays urinary tract infections in acute spinal cord injury: a prospective, randomized, multicenter trial. PM R. 2011;3(5):408-417. PMID: 21570027. DOI: 10.1016/j.pmrj.2011.01.001.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-15 · Corrections: none

Cite this verdict

Hydrophilic intermittent catheter x fewer urinary tract infections after acute spinal cord injury Evidence Grade C card
[Chamgap] Hydrophilic intermittent catheter x fewer urinary tract infections after acute spinal cord injury — Evidence Grade C·54. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/hydrophilic-intermittent-catheter-acute-spinal-cord-injury-uti/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.